14 reports

  • Serotonin Noradrenaline Reuptake Inhibitors (SNRIs)

This report analyzes the worldwide markets for CNS Therapeutics in US$ Million by the following Product Groups: Anti-Alzheimer’s, Anti-Parkinson’s, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific,...

  • Analgesic
  • Antipsychotic
  • Therapy
  • APAC
  • World
  • R&D Progress Research and Development Brief

The study included positive control sibutramine (## mg/ kg once daily, ##. ## percent weight loss), a serotonin and noradrenaline reuptake inhibitor, which is currently marketed for the treatment of obesity.

  • Hormone
  • Obesity
  • Therapy
  • World
  • Product Initiative
  • CSTI-100 - DRUG PROFILE

The study included positive control sibutramine (## mg/ kg once daily, ##. ## percent weight loss), a serotonin and noradrenaline reuptake inhibitor, which is currently marketed for the treatment of obesity.

  • Hormone
  • Obesity
  • Therapy
  • World
  • Product Initiative
  • Nov 16, 2017: Krka presented its operating results for the period January-September 2017

The medicine from the group of combined serotonin and noradrenaline reuptake inhibitors is used to treat depression, generalised anxiety disorder and neuropathic pain in diabetes.

  • Healthcare
  • Pharmaceutical
  • Slovenia
  • Demand
  • Krka Group
  • Product Development Milestones

DEC ##, 2016: " CYMBALTA CAPSULES ##MG ## MG" (SEROTONIN-NORADRENALINE REUPTAKE INHIBITOR) APPROVED FOR AN ADDITIONAL INDICATION OF PAIN ASSOCIATED WITH OSTEOARTHRITIS Shionogi & Co., Ltd and Eli Lilly Japan K. K. announced that " CYMBALTA Capsules

  • Chronic Pain
  • Pain Relief
  • Pathology
  • Pharmaceutical
  • Therapy
  • Melanin-Concentrating Hormone Receptor 1 (G-

The study included positive control sibutramine (## mg/ kg once daily, ##. ##% weight loss), a serotonin and noradrenaline reuptake inhibitor, which is currently marketed for the treatment of obesity.

  • Hormone
  • Obesity
  • Pharmaceutical
  • Therapy
  • Vaccine
  • Preferred Drugs List, as at August 2016

The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS pricing and reimbursement specialists to provide industry players and decision makers with a thorough understanding of the rules and...

  • Healthcare
  • Hospital
  • Pharmaceutical
  • Ireland
  • Supply
  • Serotonin-Norepinephrine Reuptake Inhibitors

This study focuses on China’s Depression Treatment Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the...

  • Antidepressant
  • Hormone
  • Therapy
  • China
  • Demand
  • Serotonin-Norepinephrine Reuptake Inhibitors

China’s demand for Depression Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports,...

  • Antidepressant
  • Pharmaceutical
  • Therapy
  • China
  • Demand
  • MAJOR DEPRESSIVE DISORDER - GLOBAL DRUG FORECAST AND MARKET ASSESSMENT TO 2025

ANTIDEPRESSANT EFFICACY AND TOLERABILITY OF MILNACIPRAN, A DUAL SEROTONIN and noradrenaline reuptake inhibitor: a comparison with fluvoxamine.

  • Antidepressant
  • Depression
  • Serotonin Specific Reuptake Inhibitor
  • Therapy
  • Allergan plc
  • Jan 09, 2017: Addex ADX71441 Demonstrates Statistically Significant Efficacy in a Highly Translational Preclinical Model of Chronic Osteoarthritis Pain
  • FEATURED NEWS & PRESS RELEASES

Osteoarthritis Pain - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis Pain - Pipeline Review, H1 2017, provides an overview of the Osteoarthritis Pain (Central Nervous System) pipeline landscape. Osteoarthritis pain is the most common...

  • Chronic Disease
  • Musculoskeletal Disorder
  • Pathology
  • Pharmaceutical
  • Therapy
  • CSTI-100 - DRUG PROFILE

THE STUDY INCLUDED POSITIVE CONTROL SIBUTRAMINE (## MG/ KG ONCE DAILY, ##. ## PERCENT WEIGHT LOSS), A SEROTONIN AND NORADRENALINE REUPTAKE INHIBITOR, WHICH IS CURRENTLY MARKETED FOR THE TREATMENT OF OBESITY.

  • Digestive System Disorder
  • Pathology
  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • CSTI-100 - DRUG PROFILE

THE STUDY INCLUDED POSITIVE CONTROL SIBUTRAMINE (## MG/ KG ONCE DAILY, ##. ## PERCENT WEIGHT LOSS), A SEROTONIN AND NORADRENALINE REUPTAKE INHIBITOR, WHICH IS CURRENTLY MARKETED FOR THE TREATMENT OF OBESITY.

  • Digestive System Disorder
  • Pathology
  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • GLAXOSMITHKLINE PLC - DISCONTINUED PIPELINE PRODUCTS

The serotonin-noradrenaline reuptake inhibitors (SNRIs) are a class of drug that inhibit reuptake of both serotonin and noradrenaline.

  • Infectious Disease
  • Pathology
  • Therapy
  • Vaccine
  • GlaxoSmithKline plc